These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 16686067)

  • 61. Inhibition of adenovirus-mediated gene transfer by bronchoalveolar lavage fluid.
    Bastian A; Bewig B
    Gene Ther; 1999 Apr; 6(4):637-42. PubMed ID: 10476223
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Expression of immunoreactivity and genetic mutation in eosinophilic and ciliated metaplastic changes of endometrial glandular and stromal breakdown: cytodiagnostic implications.
    Shimizu K; Norimatsu Y; Kobayashi TK; Sakurai M; Ogura S; Yoshizawa A; Miyamoto T; Miyake Y; Aratake Y; Sakaguchi T; Ohno E
    Ann Diagn Pathol; 2009 Apr; 13(2):89-95. PubMed ID: 19302956
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Clinical significance of serum p53 antibody detection in a chemosensitivity assay in cases of human colorectal cancer].
    Takeda A; Shimada H; Nakajima K; Imaseki H; Okazumi S; Takayama W; Iwasaki K; Makino H; Natsume T; Kouno T; Kondo S; Suzuki T; Ochiai T; Isono K
    Gan To Kagaku Ryoho; 2000 Jun; 27(6):879-83. PubMed ID: 10897215
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Detection of serum autoantibodies to tumor suppressor gene p53 with a new enzyme-linked immunosorbent assay in patients with ovarian cancer.
    Marx D; Frey M; Zentgraf H; Adelssen G; Schauer A; Kuhn W; Meden H
    Cancer Detect Prev; 2001; 25(2):117-22. PubMed ID: 11341346
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Immunohistochemical detection of the gene p53 and p21 expression in cells of the malignant melanoma of the uvea].
    Tokosová E; Hermanová M; Uhmannová R; Smardová J; Hlinomazová Z
    Cesk Slov Oftalmol; 2008 Jul; 64(4):153-6. PubMed ID: 18780655
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
    Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
    Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Anti-p53 autoantibody in systemic sclerosis: association with limited cutaneous systemic sclerosis.
    Hara T; Ogawa F; Muroi E; Komura K; Takenaka M; Hasegawa M; Fujimoto M; Sato S
    J Rheumatol; 2008 Mar; 35(3):451-7. PubMed ID: 18203319
    [TBL] [Abstract][Full Text] [Related]  

  • 68. p53 overexpression and mutation in metaplastic carcinoma of the breast: genetic evidence for a monoclonal origin of both the carcinomatous and the heterogeneous sarcomatous components.
    Lien HC; Lin CW; Mao TL; Kuo SH; Hsiao CH; Huang CS
    J Pathol; 2004 Oct; 204(2):131-9. PubMed ID: 15376261
    [TBL] [Abstract][Full Text] [Related]  

  • 69. TP53 mutations in circulating free DNA from Egyptian patients with non-Hodgkin's lymphoma.
    Hosny G; Farahat N; Hainaut P
    Cancer Lett; 2009 Mar; 275(2):234-9. PubMed ID: 19046801
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial.
    Tian G; Liu J; Zhou JS; Chen W
    Anticancer Drugs; 2009 Jun; 20(5):389-95. PubMed ID: 19287305
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The predictive value of p53 and p33(ING1b) in patients with Dukes'C colorectal cancer.
    Ahmed IA; Kelly SB; Anderson JJ; Angus B; Challen C; Lunec J
    Colorectal Dis; 2008 May; 10(4):344-51. PubMed ID: 17949449
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Expression of programmed cell death proteins in patients with chronic myeloid leukemia.
    Strnad M; Brajuskovic G; Strelic N; Todoric-Zivanovic B; Stamatovic D; Tatomirovic Z; Magic Z
    J BUON; 2008; 13(3):403-8. PubMed ID: 18979557
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers.
    Müller M; Meyer M; Schilling T; Ulsperger E; Lehnert T; Zentgraf H; Stremmel W; Volkmann M; Galle PR
    Int J Oncol; 2006 Oct; 29(4):973-80. PubMed ID: 16964393
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Construction of a RU486 inducible recombinant adenoviral vector carrying murine interleukin-12 gene and experimental treatment of colonic carcinoma].
    Chen J; Liu XS; Wang F; Xue XC; Fang GE; Su CQ; Qian QJ
    Zhonghua Yi Xue Za Zhi; 2009 May; 89(20):1372-6. PubMed ID: 19671324
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers.
    Akkiprik M; Ataizi-Celikel C; Düşünceli F; Sönmez O; Gulluoglu BM; Sav A; Ozer A
    J Gastrointestin Liver Dis; 2007 Mar; 16(1):11-7. PubMed ID: 17410283
    [TBL] [Abstract][Full Text] [Related]  

  • 76. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
    Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Association of p53 Arg72Pro polymorphism and beta-catenin accumulation in mycosis fungoides.
    Bellei B; Cota C; Amantea A; Muscardin L; Picardo M
    Br J Dermatol; 2006 Dec; 155(6):1223-9. PubMed ID: 17107393
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The presence of anti-p53 antibodies in sera from patients with oesophageal carcinoma: correlation to treatment, tumour volume and survival.
    Bergström S; Dreilich M; Wagenius G; Brattström D; Larsson A; Hesselius P; Bergqvist M
    In Vivo; 2004; 18(5):615-20. PubMed ID: 15523902
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Implications of p53 gene mutations on patient survival in transitional cell carcinoma of the bladder: a long-term study.
    Salinas-Sánchez AS; Lorenzo-Romero JG; Giménez-Bachs JM; Sánchez-Sánchez F; Donate-Moreno MJ; Rubio-Del-Campo A; Hernández-Millán IR; Segura-Martín M; Atienzar-Tobarra M; Escribano-Martínez J
    Urol Oncol; 2008; 26(6):620-6. PubMed ID: 18367096
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
    Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
    Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.